An extended-release or split-dose regimen could, in theory, improve overnight brain exposure and enable target engagement at lower total daily dose. However, this remains a PK/PD speculation without human dementia biomarker support, so it is better deferred until any clinical pharmacodynamic signal is established.
No AI visual card yet
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
No clinical trials data available
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
No knowledge graph edges recorded
No comments yet. Be the first to comment!